XML 45 R32.htm IDEA: XBRL DOCUMENT v3.22.4
Collaboration and License Agreements - Amgen, Inc (Details)
$ in Thousands
3 Months Ended
Sep. 28, 2016
USD ($)
agreement
Mar. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Sep. 30, 2022
USD ($)
Jul. 31, 2020
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Revenues     $ 62,546 $ 27,439    
Contract liabilities     66,281   $ 74,099  
Amgen | Subsequent Event            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Upfront milestone payment received   $ 25,000        
Amgen | Collaboration and License agreements            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Number of agreements | agreement 2          
Amgen | Olpasiran Agreement            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Upfront payment $ 35,000          
Proceeds from the issuance of common stock 21,500          
Milestone payments $ 30,000          
Amgen | Olpasiran Agreement | Maximum            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Additional remaining development regulatory and sales milestones payments     375,000      
Amgen | Olpasiran and ARO-AMG1 Agreement            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Milestone payments           $ 20,000
Revenues     25,000 $ 0    
Contract assets     25,000      
Contract liabilities     $ 0